Lifecare ASA - Director's Dealing 2026

Lifecare ASA: Mandatory notification of trade

Reference is made to the stock exchange announcement by Lifecare ASA (the

"Company") on 1 June 2026 regarding the commencement of the exercise period

for Warrants Series 2 issued in connection with the partially underwritten

rights issue completed in January 2026. Each Warrant Series 2 entitles the

holder to subscribe for one new share in the Company at an exercise price of

NOK 0.24899 per share.

The exercise period for Warrants Series 2 commenced on 1 June 2026 and expires

at 16:30 (CEST) on 12 June 2026 (the "Exercise Period").

Warrants Series 2 are listed and tradable on Euronext Oslo Børs under the

ticker code "LIFES". The trading in Warrants Series 2 will be halted five

trading days before the end of the Exercise Period to facilitate settlement of

exercised Warrants Series 2. Warrants Series 2 will thus be tradable until

16:30 hours (CEST) on 5 June 2026.

Warrants Series 2 not sold on or before 5 June 2026 at 16:30 (CET) or not

exercised on or before 13 March 2026 at 16:30 (CET) will lapse without

compensation. Holders of Warrants Series 1 who do not exercise their warrants

may experience dilution of their shareholding in the Company.

The Company has been informed that Morten Foros Krohnstad, Chair of the Board

and primary insider of the Company, has purchased 2,000,000 Warrants Series 2

at a price of NOK 0.0157 per warrant.

Following this transaction, Morten Foros Krohnstad holds 1,600,000 shares and

2,000,000 Warrants Series 2 in the Company.

Please see the attached notification form for further details.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring systems to market. Lifecare

enables osmotic pressure as sensing principle. Lifecare's sensor technology is

suitable for identifying and monitoring the occurrence of a wide range of

analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, [email protected], +47 40 05 90 40

Petter Nielsen, CFO, [email protected], +47 92 24 74 64

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-06-03 13:15 CEST.

AI assistant